/
DCF Valuation
Base-case fair value
$5.76
Intrinsic $7.69 · 25% MOS
Current price: $1.58
Base-case summary
Our base-case DCF for Interpace Biosciences, Inc. (IDXG) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 28.4% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from the 3-year average of positive free cash flow ($4M) — TTM FCF was negative, this produces an intrinsic value of $7.69 per share. A 25% safety margin gives a fair value of $5.76, suggesting the stock is currently 265% undervalued against the $1.58 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
TTM FCF is negative ($0). Projecting from a negative base produces nonsensical results, so this model uses the 3-year average of positive FCF ($4M) as the base instead. Treat this valuation as a rough estimate — it assumes a return to historical profitability.
Model inputs
Free Cash Flow (3yr avg)
$4M
Cash & equivalents
$3M
Total debt
$1M
Shares outstanding
28M